Kali Laboratories
Represented Kali Laboratories, a developer and manufacturer of generic drugs, in the acquisition of Kali by Par Pharmaceuticals (NYSE:PRX) for $140,000,000 in cash.
Represented Kali Laboratories, a developer and manufacturer of generic drugs, in the acquisition of Kali by Par Pharmaceuticals (NYSE:PRX) for $140,000,000 in cash.